S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
Log in
NASDAQ:PTGX

Protagonist Therapeutics News Headlines

$24.82
+0.45 (+1.85 %)
(As of 01/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.94
Now: $24.82
$24.97
50-Day Range
$19.02
MA: $21.90
$25.13
52-Week Range
$5.30
Now: $24.82
$25.65
Volume559,502 shs
Average Volume506,628 shs
Market Capitalization$949.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

Headlines

Protagonist Therapeutics (NASDAQ PTGX) News Headlines Today

Source:
SourceHeadline
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at JPMorgan Chase & Co.Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at JPMorgan Chase & Co.
marketbeat.com - January 6 at 8:26 AM
Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at Piper SandlerProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by Analysts at Piper Sandler
marketbeat.com - December 16 at 7:07 AM
Protagonist Therapeutics (NASDAQ:PTGX) Raised to "Buy" at Zacks Investment ResearchProtagonist Therapeutics (NASDAQ:PTGX) Raised to "Buy" at Zacks Investment Research
marketbeat.com - November 14 at 5:00 AM
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Zacks Investment Research to HoldProtagonist Therapeutics (NASDAQ:PTGX) Downgraded by Zacks Investment Research to Hold
marketbeat.com - November 12 at 8:56 AM
HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $33.00HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $33.00
marketbeat.com - September 18 at 7:30 AM
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by BidaskClub to "Buy"Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by BidaskClub to "Buy"
marketbeat.com - August 25 at 5:29 AM
Protagonist Therapeutics (NASDAQ:PTGX) Lowered to "Sell" at Zacks Investment ResearchProtagonist Therapeutics (NASDAQ:PTGX) Lowered to "Sell" at Zacks Investment Research
marketbeat.com - August 13 at 7:03 AM
Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 7.1%Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 7.1%
americanbankingnews.com - January 14 at 8:50 PM
Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 7.5%Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 7.5%
americanbankingnews.com - January 7 at 7:42 PM
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their HoldingsProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings
finance.yahoo.com - January 7 at 11:15 AM
Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at JPMorgan Chase & Co.Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at JPMorgan Chase & Co.
americanbankingnews.com - January 6 at 8:20 AM
Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceProtagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 8:57 AM
Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.3%Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.3%
americanbankingnews.com - December 29 at 7:44 PM
MannKind (MNKD) Looks Good: Stock Adds 5.6% in SessionMannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
finance.yahoo.com - December 29 at 1:03 PM
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
finance.yahoo.com - December 16 at 7:45 AM
Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesProtagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - December 15 at 8:17 PM
Is PTGX A Good Stock To Buy Now?Is PTGX A Good Stock To Buy Now?
finance.yahoo.com - December 13 at 12:39 PM
Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common StockProtagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
prnewswire.com - December 10 at 11:57 PM
Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common StockProtagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 10 at 5:18 PM
Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population CategoriesProtagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories
finance.yahoo.com - December 7 at 11:34 AM
Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia VeraProtagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
finance.yahoo.com - December 6 at 3:30 PM
Protagonists Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia VeraProtagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
finance.yahoo.com - December 2 at 9:24 AM
Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020
finance.yahoo.com - November 30 at 7:21 AM
Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare ConferenceProtagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference
finance.yahoo.com - November 25 at 9:24 AM
Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare ConferenceProtagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference
finance.yahoo.com - November 11 at 6:00 PM
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 4 at 10:02 PM
Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate UpdateProtagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 4 at 5:02 PM
Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual MeetingProtagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting
finance.yahoo.com - November 4 at 12:01 PM
Protagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists programProtagonist Therapeutics, Janssen advance oral IL-23 receptor antagonists program
seekingalpha.com - October 30 at 9:34 AM
Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with JanssenProtagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen
finance.yahoo.com - October 29 at 6:32 PM
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseProtagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
finance.yahoo.com - October 28 at 1:58 PM
Protagonist Therapeuticss lead asset an Orphan Drug in Europe for a type of blood cancerProtagonist Therapeutics's lead asset an Orphan Drug in Europe for a type of blood cancer
seekingalpha.com - October 21 at 8:05 AM
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia VeraProtagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
finance.yahoo.com - October 21 at 8:05 AM
Protagonist Therapeutics, Inc. (PGF.SG)Protagonist Therapeutics, Inc. (PGF.SG)
au.finance.yahoo.com - October 11 at 5:05 PM
Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment ConferenceProtagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 10 at 9:01 PM
Protagonist Therapeutics to Host PTG-300 Opportunity Update WebinarProtagonist Therapeutics to Host PTG-300 Opportunity Update Webinar
finance.yahoo.com - September 2 at 7:43 PM
Can You Imagine How Protagonist Therapeutics (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM
Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?Can You Imagine How Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Feel About The 64% Share Price Increase?
finance.yahoo.com - August 25 at 1:23 PM
Protagonist Therapeutics Inc (NMQ:PTGX) price about to hit new 52-week highProtagonist Therapeutics Inc (NMQ:PTGX) price about to hit new 52-week high
uk.finance.yahoo.com - August 20 at 10:01 AM
Protagonist Appoints Sarah ODowd to Board of DirectorsProtagonist Appoints Sarah O'Dowd to Board of Directors
prnewswire.com - August 13 at 7:25 PM
Protagonist Appoints Sarah O'Dowd to Board of DirectorsProtagonist Appoints Sarah O'Dowd to Board of Directors
finance.yahoo.com - August 13 at 7:25 PM
Protagonist ramps up construction on Lower South End breweryProtagonist ramps up construction on Lower South End brewery
bizjournals.com - August 7 at 6:56 PM
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue EstimatesProtagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 6 at 10:49 PM
Protagonist EPS misses by $0.02, beats on revenueProtagonist EPS misses by $0.02, beats on revenue
seekingalpha.com - August 6 at 5:46 PM
Protagonist Therapeutics: 2Q Earnings SnapshotProtagonist Therapeutics: 2Q Earnings Snapshot
finance.yahoo.com - August 6 at 5:46 PM
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate UpdateProtagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 6 at 5:46 PM
Protagonist Therapeutics, Inc. Common StockProtagonist Therapeutics, Inc. Common Stock
www.fool.com - August 2 at 12:59 AM
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseProtagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
finance.yahoo.com - July 29 at 3:04 PM
Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?
finance.yahoo.com - June 28 at 1:24 AM
Why Protagonist Should Be On Your Radar After Latest Trial UpdateWhy Protagonist Should Be On Your Radar After Latest Trial Update
seekingalpha.com - June 26 at 7:34 AM
Stock Alert: Protagonist Therapeutics Up 10% As Hepcidin Mimetic PTG-300 Gets Orphan Drug StatusStock Alert: Protagonist Therapeutics Up 10% As Hepcidin Mimetic PTG-300 Gets Orphan Drug Status
www.nasdaq.com - June 18 at 12:20 PM
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare ConferenceProtagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - June 16 at 10:39 PM
Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The BeginningProtagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning
seekingalpha.com - June 10 at 12:59 PM
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual CongressProtagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
finance.yahoo.com - June 4 at 11:03 AM
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
www.bloomberg.com - May 26 at 5:56 PM
Analysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue ForecastsAnalysts Just Made A Major Revision To Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts
finance.yahoo.com - May 18 at 10:48 AM
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call TranscriptProtagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 3:54 AM
This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.